Sotabase

Career

· Graduate Student, Adept Lab at UC Berkeley2024–
· Aspire Lab, UC Berkeley
· Graduate Student, UC Berkeley

Publications (18)

Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
Journal of Medicinal Chemistry · 2005
149
cited
A-995662 [(R)-8-(4-methyl-5-(4-(trifluoromethyl)phenyl)oxazol-2-ylamino)-1,2,3,4-tetrahydronaphthalen-2-ol], a novel, selective TRPV1 receptor antagonist, reduces spinal release of glutamate and CGRP in a rat knee joint pain model
Pain · 2010
67
cited
Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
Bioorganic & Medicinal Chemistry · 2008
44
cited
Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists.
Bioorganic & Medicinal Chemistry Letters · 2011
42
cited
Adenosine kinase inhibitors: polar 7-substitutent of pyridopyrimidine derivatives improving their locomotor selectivity.
Bioorganic & Medicinal Chemistry Letters · 2003
38
cited
Synthesis and biological evaluation of 5-substituted and 4,5-disubstituted-2-arylamino oxazole TRPV1 antagonists.
Bioorganic & Medicinal Chemistry · 2010
32
cited
Pyridopyrimidine analogues as novel adenosine kinase inhibitors.
Bioorganic & Medicinal Chemistry Letters · 2001
29
cited
Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.
Bioorganic & Medicinal Chemistry Letters · 2007
28
cited
Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis.
ACS Medicinal Chemistry Letters · 2019
27
cited
Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists.
Bioorganic & Medicinal Chemistry · 2006
25
cited
In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
Journal of Medicinal Chemistry · 2007
22
cited
Discovery of TRPV1 antagonist ABT-116.
Bioorganic & Medicinal Chemistry Letters · 2010
19
cited
Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ring.
Bioorganic & Medicinal Chemistry Letters · 2010
18
cited
Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of pain.
Bioorganic & Medicinal Chemistry · 2022
4
cited
Discovery and SAR of 4-Aminopyrrolidine-2-carboxylic Acid Correctors of CFTR for the Treatment of Cystic Fibrosis.
Bioorganic & Medicinal Chemistry Letters · 2022
3
cited
Condensed azabicyclischeverbindungen as inhibitors of the vanilloid receptor 1 (VR1)
2003
Condensed compounds which inhibit the vanilloid receptor subtype 1 (VR1) receptor
2004
receptor inhibit - the the vanilloidrezeptorsubtyp 1 (VR1) fused azabicyclic compounds,
2004
Sotabase
John Koenig | Researcher Profile | Sotabase | Sotabase